高蛋白饮食可以防止葡萄糖皮质醇诱导的脂肪质量积累和高血糖症
Susan J Burke1,2, Heidi M Batdorf2,3, Maggie P Ducote1
1Laboratory of Immunogenetics, Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA.
International journal of molecular sciences
|May 14, 2025
概括
高蛋白饮食 (HPD) 在接受葡萄糖皮质类药物的小鼠中预防了高血糖和脂肪增加,但没有防止肌肉损失. 这种饮食方法可以帮助管理类固醇治疗的副作用.
科学领域:
- 内分泌学 在内分泌学.
- 代谢研究研究 代谢研究
- 营养科学 营养科学
背景情况:
- 葡萄糖皮质激素治疗与高血糖症和不良的身体组成变化有关,包括瘦肉质量损失和脂肪积累.
- 葡萄糖皮质醇诱导的糖尿病是类固醇治疗的常见并发症.
- 肉症和肥胖是慢性葡萄糖皮质激素暴露的显著代谢后果.
研究的目的:
- 为了研究高蛋白饮食 (HPD) 对小鼠葡萄糖皮质类药物诱导的代谢功能障碍的影响.
- 为了确定HPD是否可以减轻皮质激素的管理引起的高血糖症,肉症和脂肪积累.
- 探索HPD在葡萄糖皮质体治疗期间对代谢组织基因表达的影响.
主要方法:
- 在C57BL/6J小鼠中给予皮质.
- 高蛋白饮食 (60%卡路里) 与正常蛋白饮食 (20%卡路里) 的比较,与卡路里相匹配.
- 评估身体组成 (瘦身和脂肪质量),血糖水平和胰岛素敏感性.
- 脂肪组织和肝脏的RNA测序.
主要成果:
- 在接受皮质子治疗的小鼠中,HPD预防了脂肪质量积累和高血糖症.
- HPD并没有阻止葡萄糖皮质类药物诱导的瘦肉量减少.
- 吃高血糖饮食的小鼠没有出现高血糖症,与吃正常蛋白质饮食的小鼠不同.
- 胰岛素敏感性没有得到改善的HPD,但脂肪组织和肝脏的基因表达发生了改变.
结论:
- 高蛋白饮食可能有助于限制血糖增加和脂肪组织积累在葡萄糖皮质激素治疗期间.
- 像HPD这样的饮食干预措施可能是管理葡萄糖皮质醇治疗特定副作用的策略.
- 需要进一步的研究来了解HPD对基因表达和代谢结果的影响背后的机制.
相关概念视频
Hypoglycemia and Glucagon
143
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
143
Overview of Carbohydrate Metabolism
600
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
600
Hormones Regulating Blood Glucose
2.9K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
2.9K
Glucose Homeostasis: Regulation of Blood Glucose
1.3K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
1.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones
144
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
144
Insulin: Dosing Regimen and Adverse Effects
129
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
129


